EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Antinuclear Antibodies in Non-Rheumatic Diseases

Nikita Niranjan Kumar, Samir Ahmad Dit Al Hakim, Bogna Grygiel-Górniak

Archivum Immunologiae et Therapiae Experimentalis · 2025

DOI: 10.2478/aite-2025-0004 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Archivum Immunologiae et Therapiae Experimentalis, 2025. Verfasst von Nikita Niranjan Kumar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Rehabilitation and Internal Diseases, Poznañ University of Medical Sciences, Poznañ, Poland. Hauptthemen laut MEDLINE: Antibodies, Antinuclear, Autoimmune Diseases, Connective Tissue Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 159 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antinuclear antibodies (ANAs) are critical immunological markers commonly associated with various connective tissue diseases (CTDs). However, these autoantibodies are also detectable in healthy individuals, patients with non-rheumatic autoimmune diseases, those with viral infections, and subjects using specific medications (such as procainamide, hydralazine, and minocycline) that can lead to drug-induced ANA elevation. The standard method for ANA detection is indirect immunofluorescence, a process that requires precision and thoroughness as it assesses both titer and fluorescence patterns. Additionally, immunoblotting and enzyme-linked immunosorbent assay (ELISA) are recommended to identify specific ANAs precisely, highlighting the importance of precision in ANA detection. This review explores the advantages and limitations of current ANA detection methods. It also describes the clinical implications of ANA presence in non-rheumatic diseases, including autoimmune disorders, infectious conditions, non-autoimmune and non-infectious diseases, and autoimmune cutaneous diseases. The presence of elevated ANA titers in these contexts can complicate clinical decision-making, as the diagnostic value of ANA testing alone is limited in non-rheumatic conditions. However, despite these limitations, ANA remains a key component in diagnosing and prognosis systemic CTDs, as it can indicate disease activity, severity, and response to treatment, which is of utmost importance in rheumatology and internal medicine. This paper provides a comprehensive review of the role of ANA in non-rheumatic diseases. It focuses on ANA diagnostic and prognostic significance and offers valuable insights for clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, AntinuclearAutoimmune DiseasesConnective Tissue DiseasesHumansBiomarkersAnimalsEnzyme-Linked Immunosorbent AssayFluorescent Antibody Technique, Indirect

Stichwörter der Autor:innen

Antinuclear antibodiesAutoimmune non-rheumatic diseasesInfectious diseasesMethods of detection

Substanzen

Antibodies, AntinuclearBiomarkers

Autor:innen und Institutionen

  • Department of Rheumatology, Rehabilitation and Internal Diseases, Poznañ University of Medical Sciences, Poznañ, Poland.

Zitieren

APA

Kumar, N. N., Ahmad Dit Al Hakim, S., & Grygiel-Górniak, B. (2025). Antinuclear Antibodies in Non-Rheumatic Diseases. Archivum Immunologiae et Therapiae Experimentalis. https://doi.org/10.2478/aite-2025-0004

Vancouver

Kumar NN, Ahmad Dit Al Hakim S, Grygiel-Górniak B. Antinuclear Antibodies in Non-Rheumatic Diseases. Archivum Immunologiae et Therapiae Experimentalis. 2025. doi:10.2478/aite-2025-0004

BibTeX
@article{Kumar2025,
  author = {Kumar, Nikita Niranjan and Ahmad Dit Al Hakim, Samir and Grygiel-Górniak, Bogna},
  title = {Antinuclear Antibodies in Non-Rheumatic Diseases},
  journal = {Archivum Immunologiae et Therapiae Experimentalis},
  year = {2025},
  doi = {10.2478/aite-2025-0004}
}
Kostenlos starten →